肺鳞状细胞癌预后相关影响因素研究进展

doi:10.11904/j.issn.1002-3070.2021.04.016

摘要/Abstract

摘要： 肺鳞状细胞癌在肺癌中所占比例为20%~30%,每年在全世界造成约40万人死亡。肺鳞状细胞癌患者的预后较差,这是因为患者确诊时常常已经发展到了晚期。影响肺鳞状细胞癌预后的因素有很多,例如性别和吸烟。本研究就自身因素(吸烟情况、性别、年龄、BMI、并发症)、肿瘤因素(亚部位、转移情况)和治疗因素对肺鳞状细胞癌预后的影响做一综述。

关键词: 肺鳞状细胞癌, 预后, 影响因素

Abstract: Lung squamous cell carcinoma accounts for 20%~30% of lung cancer,causing about 400,000 deaths worldwide every year.The prognosis of patients with lung squamous cell carcinoma is poor,because patients often have advanced to advanced stage when they are diagnosed.There are many factors that affect the prognosis of lung squamous cell carcinoma,such as gender and smoking.This study reviewed the effects of own factors(smoking status,gender,age,BMI and complications),tumor factors(subsites and metastasis status)and treatment factors on the prognosis of lung squamous cell carcinoma.

Key words: Lung squamous cell carcinoma, Prognosis, Influencing factors

中图分类号:

R743.2

董晓平, 张雪, 郭冬利, 贺宇彤. 肺鳞状细胞癌预后相关影响因素研究进展[J]. 实用肿瘤学杂志, 2021, 35(4): 380-385.

DONG Xiaoping, ZHANG Xue, GUO Dongli, HE Yutong. Research progress on the related factors affecting the prognosis of squamous cell carcinoma of lung[J]. Journal of Practical Oncology, 2021, 35(4): 380-385.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.04.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I4/380

参考文献

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].CA Cancer J Clin,2018,68(6):394-424.
2 Huang G,Huang Q,Xie Z,et al.A nine-long non-coding RNA signature for prognosis prediction of patients with lung squamous cell carcin oma [J].Cancer Biomark,2019,26(3):239-247.
3 Vachani A,Sequist LV,Spira A.AJRCCM:100-year anniversary.The shifting landscape for lung cancer:past,present,and future [J].Am J Respir Crit Care Med,2017,195(9):1150-1160.
4 Senoo S,Ninomiya K,Hotta K,et al.Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan [J].Int J Clin Oncol,2019,24(5):461-467.
5 Hata A,Nakajima T,Matsusaka K,et al.A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis [J].Int J Cancer,2020,146(2):388-399.
6 Jones CD,Cummings IG,Shipolini AR,et al.Does surgery improve prognosis in patients with small-cell lung carcinoma? [J].Interact Cardiovasc Thorac Surg,2013,16(3):375-380.
7 Socinski MA,Obasaju C,Gandara D,et al.Clinicopathologic features of advanced squamous NSCLC [J].J Thorac Oncol,2016,11(9):1411-1422.
8 Gu K,Lee HY,Lee K,et al.Integrated evaluation of clinical,pathological and radiological prognostic factors in squamous cell carcinoma of the lung [J].PLoS One,2019,14(10):e0223298.
9 Kadota K,Nitadori J,Woo KM,et al.Comprehensive pathological analyses in lung squamous cell carcinoma:single cell invasion,nuclear diameter,and tumor budding are independent prognostic factors for worse outcomes [J].J Thorac Oncol,2014,9(8):1126-1139.
10 Pesch B,Kendzia B,Gustavsson P,et al.Cigarette smoking and lung cancer-relative risk estimates for the major histological types from a pooled analysis of case-control studies [J].Int J Cancer,2012,131(5):1210-1219.
11 Huang Y,Wang R,Pan Y,et al.Clinical and genetic features of lung squamous cell cancer in never-smokers [J].Oncotarget,2016,7(24):35979-35988.
12 Li J,Li H,Zhang C,et al.Integrative analysis of genomic alteration,immune cells infiltration and prognosis of lung squamous cell carcinoma(LUSC)to identify smoking-related biomarkers [J].Int Immunopharmacol,2020,89(Pt A):107053.
13 Poullis M,McShane J,Shaw M,et al.Smoking status at diagnosis and histology type as determinants of long-term outcomes of lung cancer patients [J].Eur J Cardiothorac Surg,2013,43(5):919-924.
14 Kinoshita FL,Ito Y,Morishima T,et al.Sex differences in lung cancer survival:long-term trends using population-based cancer registry data in Osaka,Japan [J].Jpn J Clin Oncol,2017,47(9):863-869.
15 Yoshida Y,Murayama T,Sato Y,et al.Gender differences in long-term survival after surgery for non-small cell lung cancer [J].Thorac Cardiovasc Surg,2016,64(6):507-514.
16 Radkiewicz C,Dickman PW,Johansson ALV,et al.Sex and survival in non-small cell lung cancer:A nationwide cohort study [J].PLoS One,2019,14(6):e0219206.
17 Chansky K,Sculie J,Crowley JJ,et al.The international association for the study of lung cancer staging project prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer [J].J Thorac Oncol,2010,4(7):792-801.
18 Watanabe K,Sakamaki K,Nishii T,et al.Gender differences in the recurrence timing of patients undergoing resection for non-small cell lung cancer [J].Asian Pac J Cancer Prev,2018,19(3):719-724.
19 Caldarella A,Crocetti E,Comin CE,et al.Gender differences in non-small cell lung cancer:a population-based study [J].Eur J Surg Oncol,2007,33(6):763-768.
20 Foegle J,Hedelin G,Lebitasy MP,et al.Specific features of non-small cell lung cancer in women:a retrospective study of 1738 cases diagnosed in Bas-Rhin between 1982 and 1997 [J].J Thorac Oncol,2007,2(6):466-474.
21 Li F,He H,Qiu B,et al.Clinicopathological characteristics and prognosis of lung cancer in young patients aged 30 years and younger [J].J Thorac Dis,2019,11(10):4282-4291.
22 Yoneyama R,Saji H,Kato Y,et al.Clinicopathological characteristics and treatment strategies for young lung cancer patients [J].Ann Transl Med,2019,7(5):100.
23 Liu M,Cai X,Yu W,et al.Clinical significance of age at diagnosis among young non-small cell lung cancer patients under 40 years old:a population-based study [J].Oncotarget,2015,6(42):44963-44970.
24 Antkowiak JG,Regal AM,Takita H.Bronchogenic carcinoma in patients under age 40[J].Elsevier,1989,47(3):391-393.
25 Zhong J,Zheng Q,Gao E,et al.Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma [J].Thorac Cancer,2018,9(2):291-297.
26 Fukumoto K,Mori S,Shintani Y,et al.Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer:a retrospective analysis of 16,503 cases in a Japanese lung cancer registry study [J].Lung Cancer,2020,149:120-129.
27 Xie HJ,Zhang X,Wei ZQ,et al.Effect of body mass index on survival of patients with stage I non-small cell lung cancer [J].Chin J Cancer,2017,36(1):7.
28 Morel H,Raynard B,d′Arlhac M,et al.Prediagnosis weight loss,a stronger factor than BMI,to predict survival in patients with lung cancer [J].Lung Cancer,2018,126(2018):55-63.
29 Gronberg BH,Sundstrom S,Kaasa S,et al.Influence of comorbidity on survival,toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy [J].Eur J Cancer,2010,46(12):2225-2234.
30 Jorgensen TL,Hallas J,Friis S,et al.Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality [J].Br J Cancer,2012,106(7):1353-1360.
31 Wang W,Dou S,Dong W,et al.Impact of COPD on prognosis of lung cancer:from a perspective on disease heterogeneity [J].Int J Chron Obstruct Pulmon Dis,2018,13:3767-3776.
32 Li C,Wu W,Chen N,et al.Clinical characteristics and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema:a systematic review and meta-analysis of 13 studies [J].J Thorac Dis,2017,9(12):5322-5334.
33 Saijo T,Ishii G,Nagai K,et al.Differences in clinicopathological and biological features between central-type and peripheral-type squamous cell carcinoma of the lung [J].Lung Cancer,2006,52(1):37-45.
34 Kinoshita T,Ohtsuka T,Hato T,et al.Prognostic factors based on clinicopathological data among the patients with resected peripheral squamous cell carcinomas of the lung [J].J Thorac Oncol,2014,9(12):1779-1787.
35 Li C,Liu J,Lin J,et al.Poor survival of non-small-cell lung cancer patients with main bronchus tumor:a large population-based study [J].Future Oncol,2019,15(24):2819-2827.
36 Badawy A,Khedr G,Omar A,et al.Site of metastases as prognostic factors in unselected population of stage IV Non-small cell lung cancer [J].Asian Pac J Cancer Prev,2018,19(7):1907-1910.
37 Okauchi S,Watanabe H,Yamada H,et al.The prognosis of lung cancer with different metastatic patterns [J].Anticancer Res,2020,40(1):421-426.
38 Nakamura H,Sakai H,Kimura H,et al.Difference in postsurgical prognostic factors between lung adenocarcinoma and squamous cell carcinoma [J].Ann Thorac Cardiovasc Surg,2017,23(6):291-297.
39 Lin MW,Huang YL,Yang CY,et al.The differences in clinicopathologic and prognostic characteristics between surgically resected peripheral and central lung squamous cell carcinoma [J].Ann Surg Oncol,2019,26(1):217-229.
40 Tamiya M,Tamiya A,Inoue T,et al.Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer:a retrospective multicenter trial [J].PLoS One,2018,13(2):e0192227.
41 李晨蔚,励新健,周增辉.ⅢA期不同 N2 状态对肺鳞癌患者预后的影响 [J].浙江医学,2008,30(12):1350-1351.
42 Hilsenbeck S,Raub W,Sridhar K.Prognostic factors in lung cancer based on multivariate analysis [J].Am J Clin Oncol,1993,16(4):301-309.
43 Yang C,Wang H,Kumar A,et al.Impact of timing of lobectomy on survival for clinical stage IA lung squamous cell carcinoma [J].Chest,2017,152(6):1239-1250.
44 Kanzaki H,Kataoka M,Nishikawa A,et al.Impact of early tumor reduction on outcome differs by histological subtype in stage III non-small-cell lung cancer treated with definitive radiotherapy [J].Int J Clin Oncol,2016,21(5):853-861.
45 Su L,Chen M,Su H,et al.Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis [J].BMC Cancer,2019,19(1):1023.
46 Wang J,Shen Q,Shi Q,et al.Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry [J].J Exp Clin Cancer Res,2014,33(109):109.
47 Calio A,Nottegar A,Gilioli E,et al.ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung [J].J Thorac Oncol,2014,9(5):729-732.
48 Rekhtman N,Paik PK,Arcila ME,et al.Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung:lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations [J].Clin Cancer Res,2012,18(4):1167-1176.
49 Soria J,Felip E,Cobo M,et al.Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung(LUX-Lung 8):an open-label randomised controlled phase 3 trial [J].The Lancet Oncology,2015,16(8):897-907.
50 Liu JH,Xu YM,Yan J.An 11-lncRNA risk scoring model predicts prognosis of lung squamous cell carcinoma [J].Eur Rev Med Pharmacol Sci,2020,24(10):5456-5464.

[1]	穆慧娟, 李海娜, 吕艺, 孙丽华, 王丽娟, 礼彦侠, 于飞, 潘国伟, 刘莉. 辽宁省三城市居民胃癌10年生存率及其影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(4): 339-343.
[2]	余幼林, 余军林, 胡超华, 沈雄山, 李卫民, 卢婷, 杨峰, 杨青青, 刘程浩. 基于生物信息学方法分析LAYN在甲状腺癌中临床预后价值及对免疫细胞浸润的影响[J]. 实用肿瘤学杂志, 2021, 35(4): 357-364.
[3]	刘文, 乔文波. 程序性死亡蛋白1及其配体在结直肠癌中的临床研究现状[J]. 实用肿瘤学杂志, 2021, 35(4): 370-375.
[4]	尹蕾, 杨旭东, 杨悦, 牛星鉴, 周晓平, 姬宏飞, 王一然. 中性粒细胞与淋巴细胞比值在非小细胞肺癌患者预后评估中的临床意义及相关机制研究[J]. 实用肿瘤学杂志, 2021, 35(2): 117-124.
[5]	秦伟, 何义富, 常娜, 钱立庭, 黄大兵, 崔亚云. 局部晚期宫颈癌放射治疗对直肠功能影响的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 170-173.
[6]	秘嘉庆, 秦倩, 马惠涵, 马梅杰, 冯勤梅. TTK在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 188-192.
[7]	张璐,陆静钰(综述),陆海军(审校). 头颈部鳞癌相关生物标志物与免疫治疗预后的关系[J]. 实用肿瘤学杂志, 2021, 35(1): 55-58.
[8]	党瑶,皇甫辉,秦艺骁,车琴,郝晓龙(综述),王斌全(审校). 头颈部鳞状细胞癌转移机制及其影响因素研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 78-82.
[9]	牛明, 于歌. 促进乳腺癌增殖转移和肿瘤干细胞特征的研究[J]. 实用肿瘤学杂志, 2020, 34(6): 518-523.
[10]	左蕊, 金路, 刘丽, 刘小嘉, 赵鹏宇, 向小燕. miR-409-3p在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 554-559.
[11]	刘恒昌, 魏然, 李春香, 刘正, 陈海鹏, 关旭, 赵志勋, 邹霜梅, 王锡山, 姜争. NOX4在结肠癌组织中的表达及与预后的关系[J]. 实用肿瘤学杂志, 2020, 34(5): 391-397.
[12]	孙小艳, 张晓艳. LncRNA-SChLAP1在结直肠癌组织中高表达的预后评估意义[J]. 实用肿瘤学杂志, 2020, 34(5): 425-429.
[13]	尹松祥. Copine-8在胃癌组织中的表达与临床病理特征及预后的相关性[J]. 实用肿瘤学杂志, 2020, 34(5): 430-435.
[14]	魏勇, 张玉海, 吕双双, 李月敏. 合并重症肌无力对胸腺瘤术后患者预后的影响[J]. 实用肿瘤学杂志, 2020, 34(4): 341-346.
[15]	谢贤鑫, 韦军, 邱佳鑫, 王聪, 姜大庆. 乳腺癌新辅助化疗残余肿瘤组织病理信息与预后分析[J]. 实用肿瘤学杂志, 2020, 34(3): 225-231.